Developer docs
API playgroundTry for free, no card

Search company profiles

Kindred Biosciences

Full company profile

uuid0004zqa

Namestring
Kindred Biosciences
Legal namestring
Elanco Animal Health Incorporated
Websiteurl
kindredbio.com
Company typeenum
Public
Founded yearint
1954
Descriptiontext

Kindred Biosciences is a veterinary biotechnology company founded in 2012 and headquartered in Burlingame, California, that develops therapeutic products targeting companion animals, specifically dogs, cats, and horses. The company operates as a for-profit entity with a headcount of 51-100 employees and was formerly publicly listed on NASDAQ under the ticker KIN before transitioning to delisted status. Its core business centers on biologic and pharmaceutical R&D for veterinary indications, though the input data does not disclose specific approved products, pipeline assets, or technical platform components.

The company has financed operations primarily through equity capital, raising approximately $62.1M cumulatively across four disclosed rounds from 2012 through 2019, with the largest being a $50M financing led by SLR Capital Partners in October 2019. Earlier rounds included $5.9M in 2013, $1M in 2012, and $5.2M from General American Investors Company in 2017. Leadership is led by founder and CEO Richard Chin, with Steve Galliker serving as CFO, indicating an R&D-intensive operating model typical of clinical-stage animal health developers.

The revenue model is not explicitly disclosed in the input data; no pricing models, customer segments, distribution channels, or named customers are provided. As a veterinary biotech, the implied commercial motion would typically involve FDA Center for Veterinary Medicine approval pathways followed by sales to veterinary hospitals, clinics, and potentially licensing to larger animal health distributors, but no evidence of an executed GTM strategy is available in the source data.

Short descriptiontext

Kindred Biosciences is a Burlingame, California veterinary biotechnology company founded in 2012 that develops therapeutic products for companion animals including dogs, cats, and horses. The firm, formerly NASDAQ-listed under KIN, employs 51-100 people and operates as a clinical-stage animal health developer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBurlingame, United States
HQ citystring
Burlingame
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
veterinary biotechnology, animal health therapeutics, biologics for companion animals, monoclonal antibodies veterinary, equine therapeutics development
Industry3 codes
PRIMARYHLAMAEAA
Companion Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAK
Biologics & Immunotherapies (Non-vaccine)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Veterinary Biopharmaceuticals
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Healthy Purpose
Description

Elanco's corporate sustainability and social impact initiative focused on making life better for animals and people

elanco.com
Core offering1 text field

Kindred Biosciences is a veterinary biotechnology company that develops biologic therapies for dogs, cats, and horses. The company's pipeline includes monoclonal antibodies and other recombinant protein therapeutics targeting conditions such as cancer, inflammatory diseases, and metabolic/endocrine disorders in companion and equine animals. Founded in 2012 and headquartered in Burlingame, California, it pursues FDA/CVM-regulated veterinary drug development pathways to bring novel biologics to the animal-health market.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Veterinary Biologic Therapeutics Pipeline (Dogs, Cats, Horses)
CategoryVeterinary Biopharmaceuticals
Description

Pipeline of biologic therapies — primarily monoclonal antibodies and other recombinant proteins — being developed for diseases in dogs, cats, and horses, including oncology, inflammatory, and metabolic/endocrine indications. Targeted at veterinary clinics and animal hospitals via regulatory (FDA/CVM) approval pathways.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kindred Biosciences

Veterinary Biopharmaceuticalskindredbio.com

Kindred Biosciences is a Burlingame, California veterinary biotechnology company founded in 2012 that develops therapeutic products for companion animals including dogs, cats, and horses. The firm, formerly NASDAQ-listed under KIN, employs 51-100 people and operates as a clinical-stage animal health developer.

What Kindred Biosciences does

Kindred Biosciences is a veterinary biotechnology company founded in 2012 and headquartered in Burlingame, California, that develops therapeutic products targeting companion animals, specifically dogs, cats, and horses. The company operates as a for-profit entity with a headcount of 51-100 employees and was formerly publicly listed on NASDAQ under the ticker KIN before transitioning to delisted status. Its core business centers on biologic and pharmaceutical R&D for veterinary indications, though the input data does not disclose specific approved products, pipeline assets, or technical platform components.

The company has financed operations primarily through equity capital, raising approximately $62.1M cumulatively across four disclosed rounds from 2012 through 2019, with the largest being a $50M financing led by SLR Capital Partners in October 2019. Earlier rounds included $5.9M in 2013, $1M in 2012, and $5.2M from General American Investors Company in 2017. Leadership is led by founder and CEO Richard Chin, with Steve Galliker serving as CFO, indicating an R&D-intensive operating model typical of clinical-stage animal health developers.

The revenue model is not explicitly disclosed in the input data; no pricing models, customer segments, distribution channels, or named customers are provided. As a veterinary biotech, the implied commercial motion would typically involve FDA Center for Veterinary Medicine approval pathways followed by sales to veterinary hospitals, clinics, and potentially licensing to larger animal health distributors, but no evidence of an executed GTM strategy is available in the source data.

Kindred Biosciences firmographics

Firmographics
Name
Kindred Biosciences
Legal name
Elanco Animal Health Incorporated
Website
https://kindredbio.com
Company type
Public
Founded year
1954
Operating status
Operating
Headcount range
1–10 employees
Short description
Kindred Biosciences is a Burlingame, California veterinary biotechnology company founded in 2012 that develops therapeutic products for companion animals including dogs, cats, and horses. The firm, formerly NASDAQ-listed under KIN, employs 51-100 people and operates as a clinical-stage animal health developer.
Ownership category
akta.pro rank

Kindred Biosciences industry classification

Industry
Product category
Veterinary Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAMAEAA
Companion Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAK
Biologics & Immunotherapies (Non-vaccine)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics

Keywords

  • Veterinary biotechnology
  • Animal health therapeutics
  • Biologics for companion animals
  • Monoclonal antibodies veterinary
  • Equine therapeutics development

Where Kindred Biosciences is headquartered

Location

Headquarters

HQ city
Burlingame
HQ country
United States
HQ region
North America

Markets served

Kindred Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Kindred Biosciences product offering

Product offering

Core offering

Kindred Biosciences is a veterinary biotechnology company that develops biologic therapies for dogs, cats, and horses. The company's pipeline includes monoclonal antibodies and other recombinant protein therapeutics targeting conditions such as cancer, inflammatory diseases, and metabolic/endocrine disorders in companion and equine animals. Founded in 2012 and headquartered in Burlingame, California, it pursues FDA/CVM-regulated veterinary drug development pathways to bring novel biologics to the animal-health market.

Differentiator

Problem solved

Functional benefit

Brands

  • Healthy Purpose: Elanco's corporate sustainability and social impact initiative focused on making life better for animals and people

Products and services

  • Veterinary Biologic Therapeutics Pipeline (Dogs, Cats, Horses) Pipeline of biologic therapies — primarily monoclonal antibodies and other recombinant proteins — being developed for diseases in dogs, cats, and horses, including oncology, inflammatory, and metabolic/endocrine indications. Targeted at veterinary clinics and animal hospitals via regulatory (FDA/CVM) approval pathways.

Companies that use Kindred Biosciences

Customer profile

Ideal customer profiles2 records

Kindred Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Kindred Biosciences partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights2 records

Kindred Biosciences competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Kindred Biosciences social profiles

Digital presence

Kindred Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kindred Biosciences leadership team

Management profile

Number of profiles

Profiles2 records

Kindred Biosciences funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kindred Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kindred Biosciences

What does Kindred Biosciences do?

Kindred Biosciences is a veterinary biotechnology company that develops biologic therapies for dogs, cats, and horses. The company's pipeline includes monoclonal antibodies and other recombinant protein therapeutics targeting conditions such as cancer, inflammatory diseases, and metabolic/endocrine disorders in companion and equine animals. Founded in 2012 and headquartered in Burlingame, California, it pursues FDA/CVM-regulated veterinary drug development pathways to bring novel biologics to the animal-health market.

Is Kindred Biosciences a public or private company?

Kindred Biosciences is a public company. It is classified as corporate owned and is currently operating.

When was Kindred Biosciences founded?

Kindred Biosciences was founded in 1954. It employs 1 to 10 people.

Where is Kindred Biosciences based?

Kindred Biosciences is headquartered in Burlingame, United States, in the North America region.

Does Kindred Biosciences have an API?

No public API is recorded for Kindred Biosciences.

What industry is Kindred Biosciences in?

Kindred Biosciences's product category is Veterinary Biopharmaceuticals. Its primary akta.pro industry code is HLAMAEAA, Companion Animal Therapeutics (Rx), with a secondary code of HLAMAEAK, Biologics & Immunotherapies (Non-vaccine). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EtnewsCan you hold it even if you have a fur allergy?... The emergence of gene-edited beagles.Researchers from Kindred Companion Sciences announced the creation of gene-edited beagles that do not produce allergy-causing proteins, with the first examples born in September 2024. These dogs could offer a solution for allergy sufferers but raise bioethical debates and concerns about impacts on shelter animals.KXAN AustinGene-edited beagles may offer option for people with dogMatt Walker and scientists at Kindred Companion Sciences used CRISPR gene editing to create two hypoallergenic beagles, named Bailey and Alfie, by switching off the gene responsible for producing allergy-causing proteins in dogs. The research, published in the CRISPR Journal, marks the first successful application of this approach in dogs, allowing Walker—who was previously allergic—to live with Bailey without allergic reactions. Years of health monitoring and commercialization work remain before hypoallergenic dogs could be sold commercially, and experts note concerns about potential negative impacts on shelter animal adoption.azcentralGene-edited beagles may be future of allergy-free dogs, company claimsKindred Companion Sciences announced in August 2026 that it bred two gene-edited beagles, Bailey and Alfie, in September 2024 using CRISPR-based precision gene editing to eliminate the major dog allergen Can f 1, claiming this is the first time genome editing has been used to modify dog allergens. Veterinary examinations showed both dogs are experiencing normal growth and development, despite the FDA not yet approving the company's gene-editing tools. The company published a study in August noting that existing hypoallergenic dog breeds do not consistently reduce environmental allergen exposure, positioning its approach as a novel solution for the 10% to 20% of the worldwide population affected by dog and cat allergies.AD HOC NEWSThe Truth About Kindred Biosciences: Why This Pet Pharma Play Still Won’t Die OnlineKindred Biosciences (ticker KIN), a pet pharmaceutical company focused on biologics for animals, was acquired and delisted from US exchanges, making it no longer actively tradeable. Despite the delisting, the company continues to trend on social media platforms as retail investors search for information about the defunct ticker, mistaking archived data for live trading opportunities. The author argues that while KIN as a stock is a closed chapter, the underlying thesis—premium, biotech-level treatments for pets—remains valid and was effectively validated by the acquisition itself.SpglobalAnimal Pharmaceuticals Industry AnalysisThe animal pharmaceuticals industry is experiencing growth driven by the introduction of blockbuster drugs for companion animals and increasing consumer spending on pet health. Companies like Zoetis, Kindred Biosciences, and PetMedix are actively developing new treatments, including monoclonal antibodies, to meet this rising demand in developed markets and China.PR NewswireAnimal Health Market to be Worth $92.8 Billion by 2030: Million InsightsThe global animal health market is projected to reach USD 92.8 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.0%, driven by rising zoonotic diseases, technological integration, and increased pet adoption. In August 2021, Elanco Animal Health acquired Kindred Biosciences to strengthen its innovation, portfolio, and productivity strategy, illustrating consolidation trends in the sector. IDEXX Laboratories reported a 12% year-on-year revenue increase driven by its Companion Animal Group diagnostics business, reflecting strong performance amid post-pandemic market conditions.Benzinga3 Stocks Insiders Are BuyingThis article profiles recent insider purchasing activity at three publicly traded companies: Primoris Services, Brightcove, and Kindred Biosciences. The purchases range from $246,100 (10,000 shares at $24.61 by Primoris Director Terry McCallister) to $420.9 million (45.5 million shares at $9.25 by Elanco Animal Health in Kindred Biosciences). The article notes that Primoris's Energy/Renewables segment recently received solar awards worth over $120 million, while Brightcove issued revenue guidance below estimates and Kindred Biosciences shares traded nearly flat over the previous month.BioSpaceElanco Closes Acquisition of Kindred BiosciencesElanco closed its acquisition of Kindred Biosciences, paying $9.25 per share for approximately $444 million. The deal adds three dermatology blockbusters expected to launch through 2025 and is expected to add about $100 million to Elanco's innovation revenue, bringing it to $600–700 million by 2025.YahooElanco Animal Health to Snap up Kindred Biosciences; Shares SoarElanco Animal Health agreed to acquire Kindred Biosciences for $440 million, paying $9.25 per share, a 52% premium. Shares of both companies rose, with KIN jumping 45.6%. The deal is expected to close in Q3 2021, subject to regulatory approvals.